
Ultragenyx’s ASO for Angelman Syndrome fails at Phase III
Ultragenyx Pharmaceutical has revealed that its Phase III Aspire study for apazunersen (GTX-102) in Angelman syndrome did not achieve its primary endpoint of change from Baseline in Bayley-4 cognitive raw score. The trial also failed to achieve the key secondary endpoint of net response in Multidomain Responder… Read More


